ArticleFrontiers in medicine2025
Comparing the clinical efficacy of hemoporfin-mediated photodynamic therapy for port wine stains in children with prior pulsed dye laser treatment history.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hemoporfin-mediated photodynamic therapy (HMME-PDT) is an effective and safe therapeutic modality for port wine stains (PWS). However, the clinical efficacy is influenced by multiple factors. This study aimed to evaluate the efficacy of HMME-PDT for children with PWS who have a prior history of pulsed dye laser (PDL) treatment. Methods: Clinical data were collected from children with PWS who received HMME-PDT treatment. The patients were divided into two groups: patients without PDL treatment history as the No PDL group and patients with a history of PDL as the Prior PDL group. The correlations between clinical efficacy and gender, age, lesion location, lesion color, dermoscopic vascular features, and number of treatments were analyzed in children with PWS. Results: A total of 216 patients were enrolled, including 100 patients in the No PDL group and 116 patients in the Prior PDL group aged between 1 and 14 years. There was no significant difference in clinical efficacy and adverse reactions of HMME-PDT treatment between the No PDL and Prior PDL groups. Both the location of lesions and dermoscopic vascular features significantly influenced the clinical efficacy of HMME-PDT for children with PWS ( Conclusion: These data indicated that PDL treatment history did not influence the clinical efficacy of HMME-PDT and supported HMME-PDT as an alternative means to treat PDL-resistant PWS in children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.